Deutsche Bank Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $14
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst Neena Bitritto-Garg has initiated coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and set a price target of $14.
December 12, 2023 | 9:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roivant Sciences received a Buy rating from Deutsche Bank with a price target of $14, indicating a positive outlook from the analyst.
The initiation of coverage by a major bank with a Buy rating typically generates positive sentiment among investors, potentially driving the stock price up in the short term. The price target of $14 suggests a significant upside from the current trading price, assuming the stock is trading below this target.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100